The DOI matches its Crossref record, with a small difference in title or year; 21 of the 21 references it cites were found in a registry or an index.
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Open accessAbstract
This study investigated the effect of subcutaneously administered oxyntomodulin on body weight in healthy overweight and obese volunteers. Participants self-administered saline or oxyntomodulin subcutaneously in a randomized, double-blind, parallel-group protocol. Injections were self-administered for 4 weeks, three times daily, 30 min before each meal. The volunteers were asked to maintain their regular diet and level of physical exercise during the study period. Subjects’ body weight, energy intake, and levels of adipose hormones were assessed at the start and end of the study. Body weight was reduced by 2.3 ± 0.4 kg in the treatment group over the study period compared with 0.5 ± 0.5 kg in the control group (P = 0.0106). On average, the treatment group had an additional 0.45-kg weight loss per week. The treatment group demonstrated a reduction in leptin and an increase in adiponectin. Energy intake by the treatment group was significantly reduced by 170 ± 37 kcal (25 ± 5%) at the initial study meal (P = 0.0007) and by 250 ± 63 kcal (35 ± 9%) at the final study meal (P = 0.0023), with no change in subjective food palatability. Oxyntomodulin treatment resulted in weight loss and a change in the levels of adipose hormones consistent with a loss of adipose tissue. The anorectic effect was maintained over the 4-week period. Oxyntomodulin represents a potential therapy for obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Oxyntomodulin activates the glucagon receptor and GLP-1 receptor and promotes weight loss through elevated energy expenditure and decreased energy intake in humans (Wynne et al, 2005(Wynne et al, , 2006)).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wynne et al, 2005
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.
Hedley, A. A., Ogden, C., Johnson, C. L., Carroll, M., Curtin, L. R., & Flegal, K. (2004) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.291.23.2847 · Cited by 4,670
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494
Self-citationGut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Self-citationGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Self-citationInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Self-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Food Fails to Suppress Ghrelin Levels in Obese Humans
English, P., Ghatei, M. A., Malik, I., Bloom, S. R., & Wilding, J. P. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8738 · Cited by 535
Self-citationOxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 475
Self-citation
Cited by
Sorted by citations
Items 201–300 of 437
Obesity, Metabolic Syndrome and Disorders of Energy Balance
Han, J. C., & Weiss, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00024-5 · Cited by 27
Druce, M. R., & Bloom, S. R. (2006) · Treatments in Endocrinology · doi:10.2165/00024677-200605050-00001 · Cited by 27
Self-citationEpidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
Short-Chain Fatty Acid Production and Functional Aspects on Host Metabolism
Tungland, B. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814649-1.00002-8 · Cited by 29
Kokkinos, A. D., Tsilingiris, D., le Roux, C. W., Rubino, F., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153960 · Cited by 28
New Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 30
Medical Therapy for Obesity—Current Status and Future Hopes
Bray, G. A. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.013 · Cited by 26
Appetite and Body Weight Regulation
Vasselli, J. R. (2012) · Wiley eBooks · doi:10.1002/9781394323142.ch8 · Cited by 25
Elvert, R., Bossart, M., Herling, A. W., Weiß, T., Zhang, B., Kannt, A., Wagner, M., Haack, T., Evers, A., Dudda, A., et al. (2018) · Endocrinology · doi:10.1210/en.2018-00399 · Cited by 25
Gut Hormone Responses to Mixed Meal Test in New-Onset Prediabetes/Diabetes After Acute Pancreatitis
Pendharkar, S. A., Singh, R. G., Cervantes, A., DeSouza, S. V., Bharmal, S. H., & Petrov, M. S. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0802-9569 · Cited by 24
Oxyntomodulin May Distinguish New-Onset Diabetes After Acute Pancreatitis From Type 2 Diabetes
Bharmal, S. H., Cho, J., Stuart, C. E., Ramos, G. C. A., Ko, J., & Petrov, M. S. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000132 · Cited by 24
A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity
Vega, R. B., Whytock, K. L., Gassenhuber, J., Goebel, B., Tillner, J., Agueusop, I., Truax, A. D., Yu, G., Carnero, E., Kapoor, N., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab118 · Cited by 24
Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 28
Wang, Z.-J., Han, Y., Zhao, F., Yang, G., Yuan, L., Cai, H.-Y., Yang, J., Hölscher, C., Qi, J., & Wu, M. (2019) · Hormones and Behavior · doi:10.1016/j.yhbeh.2019.104640 · Cited by 23
Yazawa, R., Ishida, M., Balavarca, Y., & Hennige, A. M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15064 · Cited by 27
Peripheral mechanisms in the control of appetite and related experimental therapies in obesity
Camilleri, M. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.04.011 · Cited by 23
Novel therapeutics and targets for the treatment of diabetes
Aicher, T. D., Boyd, S. A., McVean, M., & Celeste, A. J. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.1 · Cited by 21
Heard, K. R., Wu, W., Li, Y., Zhao, P., Woźnica, I., Lai, J. H.-S., Beinborn, M., Sanford, D. G., DiMare, M. T., Chiluwal, A. K., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400423p · Cited by 22
Gut–brain cross-talk in appetite regulation
Cegla, J., Tan, T., & Bloom, S. R. (2010) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32833b64a3 · Cited by 23
Self-citationŠestan-Peša, M., & Horváth, T. L. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.12.003 · Cited by 21
Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity
Soni, H. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.08.005 · Cited by 22
Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake
Elliott, J. A., Reynolds, J. V., le Roux, C. W., & Docherty, N. G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1245140 · Cited by 22
Pechenov, S., Bhattacharjee, H., Yin, D., Mittal, S., & Subramony, J. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.01.006 · Cited by 22
Kushner, R. F. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.8.1339 · Cited by 23
Pharmacotherapy for Obese Adolescents
Greydanus, D. E., Bricker, L. A., & Feucht, C. L. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.10.007 · Cited by 20
Scott, R., Tan, T., & Bloom, S. R. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00007-9 · Cited by 20
Self-citationDoes adiponectin benefit steatotic liver transplantation?
Elias-Miró, M., Massip‐Salcedo, M., Jiménez‐Castro, M. B., & Peralta, C. (2011) · Liver Transplantation · doi:10.1002/lt.22358 · Cited by 21
The effects of food components on hormonal signalling in gastrointestinal enteroendocrine cells
Bruen, C. M., O’Halloran, F., Cashman, K. D., & Giblin, L. (2012) · Food & Function · doi:10.1039/c2fo30086a · Cited by 21
Hormonal regulation of appetite
Bloom, S. R. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00320.x · Cited by 21
Self-citationG Protein-Coupled Receptors as Regulators of Energy Homeostasis
Tao, Y., Yuan, Z., & Xie, J. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386933-3.00001-7 · Cited by 21
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 22
Neuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 28
RISING STARS: Endocrine regulation of metabolic homeostasis via the intestine and gut microbiome
Meyer, R. K., & Duca, F. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0019 · Cited by 25
Emerging drugs for obesity therapy
Zanella, M. T., & Filho, F. F. R. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000200019 · Cited by 20
Li, W., Kirchner, T., Ho, G., Bonilla, F., D'Aquino, K., Littrell, J., Zhang, R., Jian, W., Qiu, X., Zheng, S., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14173 · Cited by 20
Gut–adipose tissue crosstalk: A bridge to novel therapeutic targets in metabolic syndrome?
Silva, D., & Matafome, P. N. (2020) · Obesity Reviews · doi:10.1111/obr.13130 · Cited by 22
Oxyntomodulin physiology and its therapeutic development in obesity and associated complications
Kueh, M. T. W., Chong, M. C., Miras, A. D., & le Roux, C. W. (2024) · The Journal of Physiology · doi:10.1113/jp287407 · Cited by 19
NESTOR, J. J. J., Zhang, X., Jaw‐Tsai, S., Parkes, D. G., & Becker, C. (2021) · Peptide Science · doi:10.1002/pep2.24221 · Cited by 19
de Laat, M. A., & Fitzgerald, D. M. (2023) · The Veterinary Journal · doi:10.1016/j.tvjl.2023.105967 · Cited by 20
The role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 20
Las hormonas gastrointestinales en el control de la ingesta de alimentos
Álvarez-Crespo, M., González-Matías, L. C., Gil‐Lozano, M., Paz, S. F., Romaní‐Pérez, M., Gago, E. M., & Ferrer, F. M. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)71946-1 · Cited by 22
Field, B. C. T. (2014) · British Medical Bulletin · doi:10.1093/bmb/ldu001 · Cited by 19
Gastrointestinal Hormones and Gut Endocrine Tumors
Vella, A. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00038-1 · Cited by 19
Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists
Jiang, N., Jing, L., Li, Q., Su, S.-B., Yang, Q., Zhou, F. L., Chen, X., Han, J. D. J., Tang, C., & Tang, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113118 · Cited by 18
Recent advances in the diagnosis of irritable bowel syndrome
El‐Salhy, M. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1067138 · Cited by 18
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 19
Metabolic surgery: A paradigm shift in type 2 diabetes management
Pappachan, J. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i8.990 · Cited by 19
Mucosal and hormonal adaptations after Roux-en-Y gastric bypass
Feris, F., MCRAE, A. N., Kellogg, T. A., McKenzie, T. J., Ghanem, O. M., & Acosta, A. J. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.08.020 · Cited by 18
Monfeuga, T., Norlin, J., Bugge, A. K., Galsgaard, E. D., Prada‐Medina, C. A., Latta, M. R., Veidal, S. S., Petersen, P. S., Feigh, M., & Holst, D. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101850 · Cited by 17
Golubić, R., Kennet, J., Parker, V., Robertson, D. C., Luo, D., Hansen, L. B., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15579 · Cited by 19
Self-citationLustig, R. H., & Weiss, R. (2008) · Elsevier eBooks · doi:10.1016/b978-141604090-3.50024-7 · Cited by 17
Petrov, M. S. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1931118 · Cited by 17
New agents in development for the management of obesity
Vincent, R. P., & le Roux, C. W. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01558.x · Cited by 17
Treating obesity: is it all in the gut?
Davenport, R. J., & Wright, S. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.025 · Cited by 17
All in one: Researchers create combination drugs for diabetes and obesity
Chakradhar, S. (2016) · Nature Medicine · doi:10.1038/nm0716-694 · Cited by 16
Kakouri, A., Kanti, G., Kapantais, E., Kokkinos, A. D., Lanaras, L., Farajian, P., Galanakis, C., Georgantopoulos, G., Vlahos, N., Mastorakos, G. P., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14090869 · Cited by 17
Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Sutariya, B., Patel, M. S., Patel, H., Pandey, D., Patel, D. N., Bahekar, R. H., & Jain, M. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.068 · Cited by 17
Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Kenkre, J. S., Tan, T., & Bloom, S. R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.5 · Cited by 14
Self-citationGlucagon modulates proliferation and differentiation of human adipose precursors
Cantini, G., Trabucco, M., Franco, A. D., Mannucci, E., & Luconi, M. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0095 · Cited by 15
White, N. E., Dhillo, W. S., Liu, Y. ‐., Small, C. J., Kennett, G. A., Gardiner, J., Ghatei, M. A., & Bloom, S. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00807.x · Cited by 16
Self-citationMaharjan, R., Lim, D. S., Baik, H. J., Park, H. E., Kim, M., Kim, K. H., & Jeong, S. H. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00681-y · Cited by 14
Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity
Will, S., Hornigold, D. C., Baker, D. J., Coghlan, M. P., Mesquita, M., Trevaskis, J. L., & Naylor, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.010 · Cited by 14
Possible role of intestinal stem cells in the pathophysiology of irritable bowel syndrome
El‐Salhy, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i13.1427 · Cited by 15
Thomas, L. H., Martel, E., Rist, W., Uphues, I., Hamprecht, D. W., Neubauer, H., & Augustin, R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15551 · Cited by 14
Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare, K. J. (2010) · PubMed · Cited by 14
Tackling obesity: new therapeutic agents for assisted weight loss
McFarlane, S. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s6552 · Cited by 13
Approaches to the pharmacological treatment of obesity
Salem, V., & Bloom, S. R. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.54 · Cited by 15
Self-citationMazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial
Bhattachar, S., Tham, L. S., Yan, L., Chua, L., Ng, S., Tang, Y., Ibriga, H., Ni, W., Gurbuz, S., Mather, K. J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70040 · Cited by 14
G protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 14
Vorobiev, I. I., Matskevich, V. A., Kovnir, S. V., Orlova, N. A., Knorre, V. D., Jain, S., Genkin, D. D., Габибов, А. Г., & Miroshnikov, A. I. (2012) · Biochimie · doi:10.1016/j.biochi.2012.09.024 · Cited by 13
Development of minimally invasive techniques for management of medically-complicated obesity
Rashti, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i37.13424 · Cited by 13
Camacho, R. C., You, S.-H., D’Aquino, K. E., Li, W., Wang, Y., Gunnet, J. W., Littrell, J. B., Qi, J. S., Kang, L., Jian, W., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1794687 · Cited by 12
Do glucagonomas always produce glucagon?
Albrechtsen, N. J. W., Challis, B., Damjanov, I., & Holst, J. J. (2015) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2015.794 · Cited by 12
Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Martinussen, C., Svane, M. S., Kristiansen, V. B., Holst, J. J., & Madsbad, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-51516-y · Cited by 12
Bosch, R., Petrone, M., Arends, R., Vicini, P., Sijbrands, E. J. G., Hoefman, S., & Snelder, N. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12752 · Cited by 11
The pharmacological treatment of obesity: Past, present and future
Simonyi, G., Pados, G., Medvegy, M., & Bedros, J. R. (2012) · Orvosi Hetilap · doi:10.1556/oh.2012.29317 · Cited by 12
Hormone-based therapies in the regulation of fuel metabolism and body weight
Kesty, N. C., Roth, J. D., & Maggs, D. G. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.11.1733 · Cited by 12
Retatrutide: A Triple Incretin Receptor Agonist for Obesity Management
Ray, A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2276754 · Cited by 11
Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years
Rose, F., Bloom, S. R., & Tan, T. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1646243 · Cited by 11
Self-citationATIGAN, A., Ardic, F., Fιndıkoğlu, G., Aybek, H., & Yaylalı, G. F. (2020) · Science & Sports · doi:10.1016/j.scispo.2020.03.008 · Cited by 11
Models and Strategies in the Development of Antiobesity Drugs
Agahi, A., & Murphy, K. G. (2013) · Veterinary Pathology · doi:10.1177/0300985813492801 · Cited by 11
Self-citationLee, J., & Kim, W. K. (2023) · Animals · doi:10.3390/ani13182975 · Cited by 10
Cai, X., Li, C., Zhou, J., Dai, Y., Avraham, Y., Sun, L., Liu, C., Tong, J., Wang, Y., Bi, X., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103538 · Cited by 10
Therapy for Obesity Based on Gastrointestinal Hormones
Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.339 · Cited by 10
ENHANCING THE LONGEVITY AND IN VIVO POTENCY OF THERAPEUTIC PROTEINS: THE POWER OF CTP
(2015) · Precision Medicine · doi:10.14800/pm.989 · Cited by 10
Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis
El‐Salhy, M., Umezawa, K., Hatlebakk, J. G., & Gilja, O. H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6266 · Cited by 10
Anti-obesity Drugs: From Animal Models to Clinical Efficacy
Dourish, C. T., Wilding, J. P. H., & Halford, J. C. G. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00028-x · Cited by 10
Signals Arising from the Gastrointestinal Tract that Affect Food Intake
Purhonen, A. (2008) · Cited by 10
Oxyntomodulin - past, present and future
Holst, J. J., & ROSENKILDE, M. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171393 · Cited by 12
Stachteas, P., Nasoufidou, A., Karakasis, P., Koiliari, M., Karagiannidis, E., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39691 · Cited by 11
Increased food intake with oxyntomodulin analogues
Price, S. L., MINNION, J. S., & Bloom, S. R. (2015) · Peptides · doi:10.1016/j.peptides.2015.09.006 · Cited by 9
Self-citationThe role of the gastrointestinal tract in the control of energy balance
Boguszewski, C. L., & van der Lely, A. J. (2014) · EUR Research Repository (Erasmus University Rotterdam) · doi:10.3978/j.issn.2224-4778.2014.07.01 · Cited by 9
Diet and Irritable Bowel Syndrome, with a Focus on Appetite-Regulating Gut Hormones
El‐Salhy, M., Gundersen, D., Hatlebakk, J. G., & Hausken, T. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407869-7.00001-5 · Cited by 9
Obesity, metabolic syndrome, and disorders of energy balance
Weiss, R., & Lustig, R. H. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00031-7 · Cited by 9
Pharmacological Treatment of the Overweight Patient
(2007) · Humana Press eBooks · doi:10.1007/978-1-59745-431-5_9 · Cited by 9
Wan, H., Xu, N., Wang, L., Liu, Y., Fatahi, S., Sohouli, M. H., & Guimarães, N. S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01501-x · Cited by 8
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 11
Pharmacologic management of obesity
Kushner, R. F. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23366 · Cited by 9
Metadata
- Authors
- Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Hammersmith Hospital (GB)
- Department of Dietetics, Imperial College Faculty of Medicine, Hammersmith Hospital, London, U.K
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2005-08-01
- Volume
- 54
- Issue
- 8
- Pages
- 2390-2395
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2154497567
- Cited by
- 435
- References
- 21
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 17 · 2023: 24 · 2022: 10 · 2021: 24 · 2020: 22 · 2019: 16 · 2018: 26 · 2017: 17 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 31 · 2012: 26
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- oxyntomodulin, obesity, weight loss, subcutaneous administration, energy intake, leptin, adiponectin, adipose tissue, anorectic effect, palatability, appetite regulation
- MeSH terms
- Adipose Tissue, Adolescent, Adult, Blood Glucose, Body Composition, Energy Intake, Diet, Double-Blind Method, Eating, Glucagon-Like Peptides, Female, Humans, Injections, Subcutaneous, Insulin, Kinetics, Male, Middle Aged, Obesity, Self Administration, Weight Loss, Exercise, Leptin, Intercellular Signaling Peptides and Proteins, Adiponectin, Oxyntomodulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
